Actualizado 30/05/2008 09:45 CET
- Comunicado -

Pertuzumab With Herceptin(R) Shows Impressive Results in Women With Advanced HER2-Positive Breast Cancer (y 2)

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Additional information is available on the Internet at



(1) Gelmon K, Fumoleau P, Verma S, Wardley A, Conte PF, Miles D, Gianni L, McNally VA, Ross GA and Baselga J. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 1026)

(2) World Health Organization,

(3) Objective response rate in a Phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with Trastuzumab (T) in patients (Pts) with HER2 positive metastatic breast cancer (MBC) which has progressed during treatment with trastuzumab -- J. Baselga. ASCO 2007 oral presentation.

For further information: Corinne Fruendt, F. Hoffmann-La Roche Ltd. Tel: +41(0)616-870-236, Mob: +41(0)795-937-216,; Peter Flynn, Axon Communications, Tel: +44(0)20-8439-9477, Mob: +44(0)780-939-0667,

Mejora la comunicación de tu empresa con Europa Press Comunicación